---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-082709"
form_type: "8-K"
ticker: "EQ"
cik: "0001746466"
company_name: "Equillium, Inc."
filed_at: "2024-04-01T23:59:59+00:00"
generated_at: "2026-06-04T04:47:11.109887+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Equillium reports positive Phase 1b itolizumab data in lupus nephritis

## Summary
- Topline data: 16 patients; baseline mean UPCR 4.9 g/g → ~73% reduction; overall response rate 81.3% (CR+PR).
- Complete response in 37.5%, partial response in 43.8%; ORR comparable to Phase 3 AURORA1 voclosporin study.
- Safety: mostly mild/moderate TEAEs (lymphopenia, peripheral edema); no treatment-related serious AEs; >80% steroid taper.
- Data triggers Ono's option to acquire itolizumab; decision expected H2 2024.

## SEC filing metadata
- accession: 0001193125-24-082709
- form_type: 8-K
- ticker: EQ
- cik: 0001746466
- company_name: Equillium, Inc.
- filed_at: 2024-04-01T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1746466/000119312524082709/0001193125-24-082709-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1746466/000119312524082709/d819425d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-082709
- JSON: https://secwatch.observer/filing/0001193125-24-082709.json
- Plain text: https://secwatch.observer/filing/0001193125-24-082709.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.